Source disclosure: February 09, 2026
Medical Data Vision Co., Ltd. [3902.T]
TOKYO — Medical Data Vision Co., Ltd., listed on the Tokyo Stock Exchange under code number 3902, announced its consolidated earnings results for the fiscal year ending December 2025 and provided updates on its business outlook. The company's board supports a tender offer initiated by Nippon Life Insurance Company and recommends shareholders to tender their shares.
For the fiscal year ended December 2025, Medical Data Vision reported a consolidated revenue of ¥6.539 billion, marking an increase of 10.7% from the previous fiscal year. Operating income stood at ¥349 million, while ordinary income reached ¥360 million. Net income attributable to parent company shareholders was recorded at ¥280 million. In contrast, the prior fiscal year saw significant losses across all key metrics, with operating income plummeting by 99.8%, ordinary income showing negative figures, and net income falling sharply to a loss of ¥791 million.
The company also highlighted changes in its cash flow dynamics over the period. Cash flows from operations increased significantly to ¥782 million compared to a deficit of ¥877 million in the previous year. However, cash outflows due to investment activities were higher at ¥96 million versus ¥592 million last year. Financial activities showed a reduction in cash outflow to ¥319 million from ¥399 million previously, resulting in an overall positive change in cash and cash equivalents balance to ¥1.713 billion from ¥1.347 billion.
Regarding dividends, the company did not distribute any dividends during the fiscal year 2025, following the announcement made on December 15, 2025, regarding the cancellation of the final dividend payment. This decision aligns with the ongoing public tender offer by Nippon Life Insurance Company, which is expected to lead to delisting of Medical Data Vision’s stock. As a result, no dividend forecast has been provided for the fiscal year 2026.
Medical Data Vision's management expects that the public tender offer and subsequent procedures will culminate in the delisting of the company's shares. Consequently, no forecasts have been given for the fiscal year 2026. Additionally, the company noted that there were no material changes in the scope of consolidation during the reporting period and no revisions to accounting policies or estimates affecting the financial statements.
The company's total assets as of December 2025 amounted to ¥4.778 billion, with equity standing at ¥3.111 billion, maintaining a solid capital adequacy ratio of 64.4%. These figures reflect slight adjustments from the previous year but indicate stable financial health despite the ongoing restructuring process.
AI-translated content. 🟢 Confidence: High See terms • Original filing